

BELVIQ®

BELVIQ® (lorcaserin HCl) is a selective serotonin 2C (5-HT_{2C}) receptor agonist that is believed to work in the brain to promote satiety. The drug is available for use in the chronic weight management of certain obese or overweight adults as an adjunct to a reduced calorie diet and increased physical activity.

The New York State Department of Health will make a determination whether or not to add this drug to the Medicaid benefit package.

Dossier sources of evidence already submitted:

The following evidence was recently submitted to the Department:

1. Apovian C, Arrone L, Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2015 DOI: 10.1210/jc.2014-3415.
2. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. *J Clin Endocrinol Metab*. Oct 2011; 96(10): 3067-3077.
3. Garvey WT, Garber AJ, Mechanick JL, Bray GA, Dagogo-Jack S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. *Endocrine Practice*. 2014; 20(9): 977-989.
4. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guidelines for the Management of Overweight and Obesity in Adults. *Circulation*. 2014; 129: S102-S138.
5. National Institutes of Health, National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 2000.
6. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. *Obesity (Silver Spring)*. Jul 2012; 20(7): 1426-1436.
7. Seger JC, Horn DB, Westman EC, Lindquist R, Scinta W, Richardson LA, Primack C, Bryman DA, McCarthy W, Hendricks E, Sabowitz BN, Schmidt SL, Bays HE. American Society of Bariatric Physicians Obesity Algorithm: Adult Adiposity Evaluation and Treatment 2013.
8. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. *N Engl J Med*. Jul 15 2010; 363(3): 245-256.
9. Wales K and Brissette I. Adult overweight and obesity in New York State: 2000-2010. Bureau of Chronic Disease Evaluation and Research. Available at:
https://www.health.ny.gov/prevention/obesity/statistics_and_impact/docs/2000-2010_adult_obesity.pdf.
10. Wang F, McDonald T, Bender J, et al. Association of healthcare costs with per unit body mass index increase. *J Occup Environ Med*. 2006 Jul; 48(7): 668-74.
11. Wang Z, Li X, Powers A, et al. Health-related quality of life in overweight and obese patients treated with lorcaserin. Presented at ObesityWeek 2013; Nov 12-16; Atlanta, GA. Abstract T-753-P.

12. Wang Z, Li X, Knoth R, et al. Cost implication of using lorcaserin in weight management prior to bariatric surgery. Presented at ISPOR 2015; May 16-20; Philadelphia, PA. Abstract PSY21.
13. Weiner J, Goodwin S, Chang HY, et al. Impact of Bariatric Surgery on Health Care Costs of Obese Persons. *JAMA Surg.* 2013 Jun; 148(6): 555-62.
14. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic Assessment of Cardiac Valvular Regurgitation with Lorcaserin from Analysis of Three Phase 3 Clinical Trials. *Circ Cardiovasc Imaging.* 2013; 6(4): 560-7.